BioSpace News Archive

Xilio Therapeutics, Inc. announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.

Regeneron Pharmaceuticals, Inc. announced positive data from three independent cohorts evaluating an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® in adults with advanced melanoma.

Astellas Pharma Inc. will share new research from across its expanding portfolio of approved and investigational cancer therapies during the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6.

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.

I-Mab announced encouraging results from the Phase 1b/2 study evaluating uliledlimab, the Company’s proprietary and highly differentiated CD73 antibody, in combination with toripalimab, a PD-1 antibody, in patients with treatment-naïve advanced non-small cell lung cancer, and exploring the potential value of CD73 expression as a predictive biomarker.

Biotheryx, Inc. announced two poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online.

Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.

Evaxion Biotech A/S unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of three abstracts on the American Society of Clinical Oncology website.

PDS Biotechnology Corporation announced promising interim data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer.